High-dose carvedilol therapy for mechanical circulatory assisted patients

Journal of Artificial Organs

Volumn 13, Issue 2, 2010, Pages 88-91

  Nishimura, Takashi ^a   Kyo, Shunei ^a  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

Bridge to recovery; Carvedilol; Left ventricular assist device

Indexed keywords

CARVEDILOL; LISINOPRIL; SPIRONOLACTONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAZOLE DERIVATIVE; PROPANOLAMINE DERIVATIVE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DEVICE THERAPY; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEART ASSIST DEVICE; HEART FAILURE; HUMAN; MALE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; AGED; MIDDLE AGED;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; CARBAZOLES; FEMALE; HEART FAILURE; HEART-ASSIST DEVICES; HUMANS; MALE; MIDDLE AGED; PROPANOLAMINES; TREATMENT OUTCOME;

EID: 77956483925     PISSN: 14347229     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10047-010-0495-y     Document Type: Article

References (18)

1. Goldstein D, Oz M, Rose E. Implantable left ventricular assist devices. N Engl J Med. 1998;339:1522-33.
2. Korfer R, El-Banayosy A, Arusoglu L. Single-center experience with the thoratec ventricular assist devices. J Thorac Cardiovasc Surg. 2000;119:596-600.
3. Pennington D, McBride L, Peigh P. Eight years' experience with bridging to cardiac transplantation. J Thorac Cardiovasc Surg. 1994;107:472-81.
4. Zaroff JG, Rosengard BR, Armstrong WF, Babcock WD,D'Alessandro A, Dec GW, et al. Consensus conference report:maximizing use of organs recovered from the cadaver donor: cardiac recommendations, March 28-29, 2001, Crystal City, VA. Circulation. 2002;106:836-41.
5. Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, et al. Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med.2001;345:1435-43.
6. Frazier OH, Benedict CR, Radovancevic B, Bick RJ, Capek P,Springer WE. Improved left ventricular function after chronic left ventricular unloading. Ann Thorac Surg. 1996;62:675-81.
7. Wohlschlaegera J, Schmitza KJ, Schmidc C, Schmida KW, Keulb K, Takedad A, et al. Reverse remodeling following insertion of left ventricular assist devices (LVAD): a review of the morphological and molecular changes. Cardiovasc Res. 2005;68:376-86.
8. Birks EJ, Tansley PD, Hardy J, George RS, Bowles CT, Burke M,et al. Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med. 2006;355:1873-84.
9. Hori M, Sasayama S, Kitabatake A, Toyo-oka T, Handa S, Yo-koyama M, et al. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am Heart J. 2004;147:324-30.
10. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB,Hershberger RE, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation. 1996;94:2807-16.
11. Nishimura M, Ogiwara M, Ishikawa M, Imanaka K, Okamura N, Kato M, et al. Successful bridge to resynchronization therapy with a left ventricular assist system in a patient with idiopathic dilated cardiomyopathy. J Artif Organs. 2005;8:210-3.
12. Gojo S, Kyo S, Nishimura S, Komiyama N, Kawai N, Bessho M, et al. Cardiac resurrection after bone-marrow-derived mononu-clear cell transplantation during left ventricular assist devicesupport. Ann Thorac Surg. 2007;83:661-2.
13. Zafeiridis A, Jeevanandam V, Houser SR, Margulies KB. Regression of cellular hypertrophy after left ventricular assist device support. Circulation. 1998;98:656-62.
14. Muller J, Wallukat G, Weng YG, Dandel M, Spiegelsberger S, Semrau S, et al. Weaning from mechanical cardiac support in patients with idiopathic dilated cardiomyopathy. Circulation.1997;96:542-9. (Pubitemid 27329431)
15. Bruckner BA, Razeghi P, Stetson S, Thompson L, Lafuente J, Entman M, et al. Degree of cardiac fibrosis and hypertrophy at time of implantation predicts myocardial improvement during left ventricular assist device support. J Heart Lung Transplant. 2004;23:36-42.
16. Xie HG, Kim RB, Wood AJJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol. 2001;41:815-50.
17. Simon MA, Kormos RL, Murali S, Nair P, Heffernan M, Gorcsan J, et al. Myocardial recovery using ventricular assist devices: prevalence, clinical characteristics, and outcomes. Circulation. 2005;112:32-6.
18. Krum H, Sackner-Bernstein JD, Goldsmith RL, Kukin ML,Schwartz B, Penn J, et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation. 1995;92:1499-506.